Doxorubicin-induced Cardiotoxicity and Cardioprotective Agents: Classic and New Players in the Game / Felipe dos Santos Arruda, Fernanda Dias Tomé, Marina Pacheco Miguel, Liliana Borges de Menezes, Patrícia Resende Alo Nagib, Erica Carolina Campos, Danilo Figueiredo Soave, Mara Rúbia Nunes Celes
Doxorubicin (DOX) is a cytostatic antibiotic from the class of anthracyclines widely used in chemotherapeutic cancer treatments. Despite the efficiency against several types of cancer, the use of DOX remains limited due to the side effects, especially cardiotoxicity. Among the DOX administration strategies, there are the “classic players” such as nanoparticles and polymers, which are capable of DOX delivery directly to interesting neoplastic regions. On the other hand, the “new players” such as phytochemicals and probiotics emerged with the proposal to react with DOX free radicals, reducing the oxidative stress, inflammatory and apoptotic process. Thus, this review aims to report the studies involving these classics and new players along the years that focus on improved administration and reduction of DOX-induced cardiotoxicity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Current pharmaceutical design - 25(2019), 2, Seite 109- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
dos Santos Arruda, Felipe [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (10 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL009082670 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL009082670 | ||
| 003 | DE-627 | ||
| 005 | 20231128152818.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220323s2019 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL009082670 | ||
| 035 | |a (KFL)prod_DARH_.9F2AB07FC251AAF47B3B9230BF16282F875EEDF1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a dos Santos Arruda, Felipe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Doxorubicin-induced Cardiotoxicity and Cardioprotective Agents: Classic and New Players in the Game |c Felipe dos Santos Arruda, Fernanda Dias Tomé, Marina Pacheco Miguel, Liliana Borges de Menezes, Patrícia Resende Alo Nagib, Erica Carolina Campos, Danilo Figueiredo Soave, Mara Rúbia Nunes Celes |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (10 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Doxorubicin (DOX) is a cytostatic antibiotic from the class of anthracyclines widely used in chemotherapeutic cancer treatments. Despite the efficiency against several types of cancer, the use of DOX remains limited due to the side effects, especially cardiotoxicity. Among the DOX administration strategies, there are the “classic players” such as nanoparticles and polymers, which are capable of DOX delivery directly to interesting neoplastic regions. On the other hand, the “new players” such as phytochemicals and probiotics emerged with the proposal to react with DOX free radicals, reducing the oxidative stress, inflammatory and apoptotic process. Thus, this review aims to report the studies involving these classics and new players along the years that focus on improved administration and reduction of DOX-induced cardiotoxicity | ||
| 700 | 1 | |a Tomé, Fernanda Dias |e verfasserin |4 aut | |
| 700 | 1 | |a Miguel, Marina Pacheco |e verfasserin |4 aut | |
| 700 | 1 | |a de Menezes, Liliana Borges |e verfasserin |4 aut | |
| 700 | 1 | |a Nagib, Patrícia Resende Alo |e verfasserin |4 aut | |
| 700 | 1 | |a Campos, Erica Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Soave, Danilo Figueiredo |e verfasserin |4 aut | |
| 700 | 1 | |a Celes, Mara Rúbia Nunes |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical design |d Hilversum : Bentham Science Publ., 2000 |g 25(2019), 2, Seite 109- |h Online-Ressource |w (DE-627)KFL000006327 |w (DE-600)2034245-7 |w (DE-576)273880217 |x 1873-4286 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2019 |g number:2 |g pages:109- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1381-6128&volume=25&issue=2&spage=109 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_DARH_01 | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2019 |e 2 |h 109- | ||